Search clinical trials for: Imatinib

Total 1419 results

Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Neoplasms

China
The First Affiliated Hospital of Xiamen University

Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

China
University of Texas Southwestern Medical Center

Recruiting

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Advanced Squamous Non Small Cell Lung Cancer

United States
Assistance Publique - Hôpitaux de Paris
Group for Research in Adult Acute Lymphoblastic Leukemia

Completed

Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Leukemia, Lymphocytic

France
Agenus Inc.

Terminated

AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

Leukemia, Myeloid, Chronic

United States, United Kingdom
Zhejiang Cancer Hospital

Unknown

A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

Colorectal Cancer

China
Third Military Medical University

Not yet recruiting

Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Small Cell Lung Cancer
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; American...

Completed

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States
Children's Hospital Medical Center, Cincinnati

Terminated

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Graft Versus Host Disease (GVHD) | Diagnoses That Require Stem Cell Transplant

United States
Beijing Sanbo Brain Hospital

Recruiting

Apatinib Combined With Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

Recurrent Medulloblastoma

China
Jiangsu Cancer Institute & Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Rigel Pharmaceuticals

Completed

Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

Rheumatoid Arthritis

United States, Mexico
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Gastric Cancer

China
Fuzhou General Hospital

Terminated

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Nonsmall Cell Lung Cancer

China
Huashan Hospital
Boehringer Ingelheim

Not yet recruiting

Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Chordoma of Clivus

China
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
Boehringer Ingelheim

Completed

Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy (LUX-Bladder 1)

Urologic Neoplasms

Spain, France, Italy
Boehringer Ingelheim

Completed

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
Boehringer Ingelheim

Completed

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Carcinoma, Non-Small-Cell Lung

Hong Kong, China, Taiwan, Singapore, India
Zhejiang Cancer Hospital

Unknown

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Treatment for Advanced Esophagus Cancer

Advanced Esophagus Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Osteosarcoma, Advanced

China
Huai'an First People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib in Metastatic Esophageal Cancer

Esophageal Cancer

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Breast Neoplasms

China
University of Patras

Completed

High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Platelet Reactivity

Greece
Nepal Health Research Council
World Health Organization

Recruiting

Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal

COVID-19

Nepal
University of Bologna
Novartis; Schering-Plough

Terminated

Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)

Chronic Myeloid Leukemia
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Gastric Cancer | Randomized Controlled Study

China
National University Hospital, Singapore

Not yet recruiting

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Squamous Cell Carcinoma

Singapore
Jiangsu HengRui Medicine Co., Ltd.
Eighty-One Hospital of People's Liberation Army

Completed

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Peking University

Unknown

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Fujian Cancer Hospital

Unknown

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma
Fudan University

Unknown

Apatinib for Advanced Biliary Carcinoma

Biliary Tract Neoplasms

China
Universitätsmedizin Mannheim

Completed

Predictors for Bronchoalveolar Lavage (BAL) Recovery Rate Derived From Quantified Computed Tomography (qCT)

Pneumonia | Interstitial Lung Disease | Malignant Neoplasm
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Malignant Melanoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Biliary Tract Cancer

China
Boehringer Ingelheim

Completed

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Canada
National Taiwan University Hospital

Unknown

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Triple Negative Breast Cancer

Taiwan
Sunnybrook Health Sciences Centre
University of British Columbia; AbbVie; World Health Organization; Apotex Inc.; Arch...

Active, not recruiting

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)

COVID-19

Canada
Sun Yat-sen University

Unknown

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study (GITIC)

Gastrointestinal Cancers

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Recurrent Glioma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Massachusetts General Hospital
National Comprehensive Cancer Network

Unknown

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Non Small Cell Lung Cancer

United States

Search clinical trials for: Imatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations